What Is Nerandomilast (Jascayd)?
Health ConditionsLung & Respiratory

What Is Nerandomilast (Jascayd)?

What Is Nerandomilast (Jascayd)?
Boehringer Ingelheim
By
Updated on October 21, 2025
by
Nerandomilast (Jascayd) is a new oral medication used to treat adults with idiopathic pulmonary fibrosis (IPF). The U.S. Food and Drug Administration (FDA) approved nerandomilast in 2025. It’s the first new treatment for IPF in more than a decade.

IPF is an incurable condition that causes scarring of the lungs. The damage worsens over time and makes it hard to catch your breath. As IPF progresses, it becomes difficult to breathe, even at rest.


Nerandomilast is in a class of drugs called phosphodiesterase 4B (PDE4B) inhibitors. It helps slow the lung function decline in IPF. This can help people with IPF feel better for longer.

How Does Nerandomilast Work?

Nerandomilast works by blocking the enzyme PDE4B. When PDE4B is overactive, it can cause inflammation and tissue damage. Targeting the PDE4B enzyme helps slow lung scarring.

In clinical trials, people who took nerandomilast experienced a slower decline in lung function than those who took a placebo pill. That means the medication kept their lungs working better over time. While it doesn’t cure IPF, nerandomilast can delay its progression.

What Are the Possible Side Effects of Nerandomilast?

Like most medications, nerandomilast can cause side effects. The most common issues reported are:

  • Diarrhea
  • Weight loss
  • Headache
  • COVID-19
  • Poor appetite
  • Vomiting
  • Nausea
  • Upper respiratory infection
  • Back pain
  • Fatigue
  • Dizziness
  • Depression

Are There Any Risks Related to Nerandomilast?

In clinical trials, nerandomilast was safe and well tolerated.

Before you take nerandomilast, tell your doctor about all the medical conditions you have, especially any kidney or liver issues.

Also, let your healthcare provider know if you:

  • Are pregnant
  • Plan to become pregnant
  • Are breastfeeding
  • Plan to breastfeed

It’s not known if nerandomilast can harm a fetus or pass into breast milk. Some data suggests the medication could cause a miscarriage.

Nerandomilast is intended for adults. Doctors don’t know if it’s safe or effective in children.

This medication may affect the way other drugs work. Tell your healthcare provider about all the prescription, nonprescription, recreational (including illegal), herbal, nutritional, or dietary drugs you’re taking while using nerandomilast. Your doctor may have to adjust your dosage if you also take medications called CYP3A inhibitors or CYP3A inducers.

If you take too much nerandomilast, call your doctor or poison control at 800-222-1222, or go to the nearest emergency room right away.


How Do You Take Nerandomilast?

Nerandomilast comes as a tablet to take by mouth. You can take this drug with or without food. If you can’t swallow the tablet, it can be mixed with water to drink. Follow the instructions on your package label carefully.

The recommended dosage is 18 milligrams (mg) about every 12 hours. Your doctor can lower your dose if you experience side effects.

If you miss a dose of nerandomilast, skip it and take your next dose at the scheduled time. Don’t double up on doses.

The Takeaway

  • Nerandomilast is the first new treatment approved for IPF in more than 10 years.
  • The medication doesn’t cure IPF, but it can slow how fast it progresses.
  • Generally, nerandomilast causes mild side effects, with diarrhea being the most common.
  • Always discuss all the drugs you’re taking with your healthcare provider.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade. Boehringer Ingelheim. September 10, 2025.
  2. Pulmonary Fibrosis Progression and Exacerbation. American Lung Association. June 7, 2024.
  3. Kolb M et al. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. European Respiratory Review. February 23, 2023.
  4. Jascayd (nerandomilast tablets), for oral use. U.S. Food and Drug Administration. October 2025.
  5. McNulty R. FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis. AJMC. October 7, 2025.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network

David Mannino, MD

Medical Reviewer

David Mannino, MD, is the chief medical officer at the COPD Foundation. He has a long history of research and engagement in respiratory health.

After completing medical training as a pulmonary care specialist, Dr. Mannino joined the Centers for Disease Control and Prevention (CDC) Air Pollution and Respiratory Health Branch. While at CDC, he helped to develop the National Asthma Program and led efforts on the Surveillance Reports that described the U.S. burden of asthma (1998) and COPD (2002).

After his retirement from CDC in 2004, Mannino joined the faculty at the University of Kentucky, where he was involved both clinically in the College of Medicine and as a teacher, researcher, and administrator in the College of Public Health. He served as professor and chair in the department of preventive medicine and environmental health from 2012 to 2017, with a joint appointment in the department of epidemiology.

In 2004, Mannino helped to launch the COPD Foundation, where he served as a board member from 2004 through 2015, chairman of the Medical and Scientific Advisory Committee from 2010 through 2015, and chief scientific officer from 2015 to 2017.

Mannino has over 350 publications and serves as an associate editor or editorial board member for the following journals: American Journal of Respiratory and Critical Care Medicine, Chest, Thorax, European Respiratory Journal, and the Journal of the COPD Foundation. He was also a coauthor of the Surgeon General’s Report on Tobacco in 2008 and 2014.

See full bio
julie-marks-bio

Julie Lynn Marks

Author

Julie Marks is a freelance writer with more than 20 years of experience covering health, lifestyle, and science topics. In addition to writing for Everyday Health, her work has been featured in WebMD, SELF, Healthline, A&E, Psych Central, Verywell Health, and more. Her goal is to compose helpful articles that readers can easily understand and use to improve their well-being. She is passionate about healthy living and delivering important medical information through her writing.

Prior to her freelance career, Marks was a supervising producer of medical programming for Ivanhoe Broadcast News. She is a Telly award winner and Freddie award finalist. When she’s not writing, she enjoys spending time with her husband and four children, traveling, and cheering on the UCF Knights.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network